BRPI1012004A2 - "forma farmacêutica" - Google Patents
"forma farmacêutica"Info
- Publication number
- BRPI1012004A2 BRPI1012004A2 BRPI1012004A BRPI1012004A BRPI1012004A2 BR PI1012004 A2 BRPI1012004 A2 BR PI1012004A2 BR PI1012004 A BRPI1012004 A BR PI1012004A BR PI1012004 A BRPI1012004 A BR PI1012004A BR PI1012004 A2 BRPI1012004 A2 BR PI1012004A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical form
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0909680.1A GB0909680D0 (en) | 2009-06-05 | 2009-06-05 | Dosage form |
| PCT/GB2010/050948 WO2010140007A2 (en) | 2009-06-05 | 2010-06-07 | Dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1012004A2 true BRPI1012004A2 (pt) | 2016-05-10 |
Family
ID=40936947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1012004A BRPI1012004A2 (pt) | 2009-06-05 | 2010-06-07 | "forma farmacêutica" |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9814679B2 (pt) |
| EP (1) | EP2437729B1 (pt) |
| JP (1) | JP5635082B2 (pt) |
| KR (1) | KR101816130B1 (pt) |
| CN (2) | CN102481260A (pt) |
| AU (1) | AU2010255502B2 (pt) |
| BR (1) | BRPI1012004A2 (pt) |
| CA (1) | CA2764517C (pt) |
| EA (1) | EA022801B1 (pt) |
| ES (1) | ES2713957T3 (pt) |
| GB (1) | GB0909680D0 (pt) |
| IL (1) | IL216748A0 (pt) |
| MX (1) | MX2011012929A (pt) |
| MY (1) | MY173629A (pt) |
| NZ (1) | NZ596879A (pt) |
| SG (2) | SG10201402810XA (pt) |
| WO (1) | WO2010140007A2 (pt) |
| ZA (1) | ZA201109221B (pt) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
| EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US8877241B2 (en) | 2003-03-26 | 2014-11-04 | Egalet Ltd. | Morphine controlled release system |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| NZ580972A (en) | 2007-06-04 | 2012-02-24 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
| JP5965583B2 (ja) * | 2007-08-13 | 2016-08-10 | インスピリオン デリバリー テクノロジーズ エルエルシー | 乱用抵抗性医薬組成物、その使用方法および作製方法 |
| JP5774853B2 (ja) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 医薬投薬形 |
| MX2010012039A (es) | 2008-05-09 | 2010-11-30 | Gruenenthal Gmbh | Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio. |
| WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| ES2428938T3 (es) | 2009-07-22 | 2013-11-12 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación |
| BR112012001547A2 (pt) | 2009-07-22 | 2016-03-08 | Gruenenthal Gmbh | forma de dosagem farmacêutica extrusada por fusão a quente |
| CA2798885C (en) | 2010-05-10 | 2014-11-18 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
| BR112012028773A2 (pt) * | 2010-05-10 | 2016-07-19 | Euro Celtique Sa | composições farmacêuticas compreendendo hidromorfona e naloxona |
| AU2011252040C1 (en) | 2010-05-10 | 2015-04-02 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
| CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
| CN103179954A (zh) | 2010-09-02 | 2013-06-26 | 格吕伦塔尔有限公司 | 包含阴离子聚合物的抗破碎剂型 |
| WO2012061779A1 (en) * | 2010-11-04 | 2012-05-10 | Abbott Gmbh & Co. Kg | Drug formulations |
| EP3124008A1 (en) | 2010-11-04 | 2017-02-01 | AbbVie Inc. | Method for producing monolithic tablets |
| GB201020895D0 (en) * | 2010-12-09 | 2011-01-26 | Euro Celtique Sa | Dosage form |
| TWI554271B (zh) * | 2010-12-28 | 2016-10-21 | 歐 賽提克股份有限公司 | 用於治療巴金森氏症的類鴉片激動劑與類鴉片拮抗劑之組合 |
| PL2736497T3 (pl) | 2011-07-29 | 2018-01-31 | Gruenenthal Gmbh | Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku |
| CA2839123A1 (en) | 2011-07-29 | 2013-02-07 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| ES2641437T3 (es) * | 2011-09-16 | 2017-11-10 | Purdue Pharma Lp | Formulaciones farmacéuticas resistentes a la manipulación indebida |
| PE20141171A1 (es) * | 2011-10-06 | 2014-09-21 | Gruenenthal Chemie | Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide |
| AU2012338872B2 (en) * | 2011-11-17 | 2017-06-22 | Grünenthal GmbH | Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer |
| MX356421B (es) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico. |
| PL2838512T3 (pl) * | 2012-04-18 | 2018-12-31 | Grünenthal GmbH | Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| BR112015000150A2 (pt) | 2012-07-06 | 2017-06-27 | Egalet Ltd | composições farmacêuticas dissuasoras de abuso de liberação controlada |
| PL2872121T3 (pl) | 2012-07-12 | 2019-02-28 | SpecGx LLC | Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania |
| CA2795324C (en) * | 2012-11-09 | 2015-07-14 | Purdue Pharma | Pharmaceutical compositions comprising hydromorphone and naloxone |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| MX371432B (es) | 2013-05-29 | 2020-01-30 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido que contiene una o mas particulas. |
| WO2014191396A1 (en) | 2013-05-29 | 2014-12-04 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| EP3068397A1 (en) | 2013-11-13 | 2016-09-21 | Euro-Celtique S.A. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
| WO2015071248A1 (en) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Abuse-proofed extended release pharmaceutical composition comprising tapentadol |
| WO2015078891A1 (en) | 2013-11-26 | 2015-06-04 | Farmaceutici Formenti S.P.A. | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| JP6403780B2 (ja) * | 2013-12-17 | 2018-10-10 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 押出成形された持続放出性乱用抑止性丸剤 |
| WO2015089530A1 (de) * | 2013-12-20 | 2015-06-25 | G.L. PHARMA GmbH | Orale darreichungsform mit verzögerter freisetzung enthaltend morphin und naloxon |
| CA2847781C (en) * | 2014-03-28 | 2019-03-12 | Purdue Pharma | Reducing drug liking in a subject |
| US20150320690A1 (en) | 2014-05-12 | 2015-11-12 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| EP3148512A1 (en) | 2014-05-26 | 2017-04-05 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| ES2963078T3 (es) * | 2014-07-03 | 2024-03-25 | SpecGx LLC | Formulaciones de liberación inmediata disuasorias del abuso que comprenden polisacáridos no celulósicos |
| AU2015290098B2 (en) | 2014-07-17 | 2018-11-01 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
| CA2983640A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles |
| BR112017021475A2 (pt) | 2015-04-24 | 2018-07-10 | Gruenenthal Gmbh | forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente |
| JP2018515455A (ja) | 2015-04-24 | 2018-06-14 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 粒子から２種の薬物の急速放出をもたらすタンパレジスタントな固定用量組合せ |
| BR112017022335A2 (pt) | 2015-04-24 | 2018-07-10 | Gruenenthal Gmbh | combinação de dose fixa inviolável que fornece rápida liberação de dois fármacos a partir de partículas e matriz |
| EP3319605A4 (en) * | 2015-07-10 | 2019-01-23 | Sun Pharma Advanced Research Company Ltd | MISS-IN-BREAKED SOLID PHARMACEUTICAL FORM OF HYDROCODON IN THE FORM OF MULTIPLE PILLS WITH IMMEDIATE RELEASE |
| AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| US11510986B2 (en) | 2016-05-13 | 2022-11-29 | Merck Patent Gmbh | Hot melt extrusion composition using direct compressible excipient as plasticizer |
| US12161754B2 (en) | 2017-12-20 | 2024-12-10 | Purdue Pharma L.P. | Abuse deterrent morphine sulfate dosage forms |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| WO2020068510A1 (en) | 2018-09-25 | 2020-04-02 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
| EP3698776A1 (en) | 2019-02-19 | 2020-08-26 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| AU2022374798B2 (en) * | 2021-10-27 | 2025-09-04 | O11 Biomedical Gmbh | Coated active ingredient formulation for controlled in-vivo uptake of co2 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2653337B1 (fr) | 1989-10-23 | 1992-02-07 | Dow Corning Sa | Element a liberation prolongee et procede pour le fabriquer. |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| US6488961B1 (en) * | 1996-09-20 | 2002-12-03 | Ethypharm, Inc. | Effervescent granules and methods for their preparation |
| DE19740983A1 (de) | 1997-09-18 | 1999-04-08 | Warner Lambert Co N D Ges D St | Verfahren zur Erschwerung der Extraktion von Wirkstoffen aus Tabletten |
| WO2000076478A1 (en) | 1999-06-14 | 2000-12-21 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| EP2517710B1 (en) | 2000-02-08 | 2015-03-25 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| WO2003013479A1 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Compositions and methods to prevent abuse of opioids |
| US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| CN100506234C (zh) | 2001-10-15 | 2009-07-01 | 凡林有限公司 | 用于治疗溃疡性结肠炎和克罗恩病的含有5-氨基水杨酸的药物组合物的制备方法 |
| LT2425824T (lt) | 2002-04-05 | 2017-07-25 | Euro-Celtique S.A. | Farmacinis preparatas, turintis oksikodono ir naloksono |
| CA2499994C (en) | 2002-09-23 | 2012-07-10 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
| WO2004087175A1 (en) | 2003-04-04 | 2004-10-14 | Pharmacia Corporation | Oral extended release compressed tablets of multiparticulates |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| ATE365545T1 (de) | 2003-08-06 | 2007-07-15 | Gruenenthal Gmbh | Gegen missbrauch gesicherte darreichungsform |
| GB0403098D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
| TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
| GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
| DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| EP3228308A1 (en) * | 2005-01-28 | 2017-10-11 | Euro-Celtique S.A. | Alcohol resistant dosage forms |
| US20070026025A1 (en) | 2005-04-12 | 2007-02-01 | Aquegel Cosmetics, Llc | Topical ointment and method for making and using same |
| WO2007013975A2 (en) | 2005-07-20 | 2007-02-01 | Pharmorx Inc. | Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications |
| DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
| KR20080089344A (ko) | 2005-12-14 | 2008-10-06 | 에프. 호프만-라 로슈 아게 | Ｃ형 간염 바이러스(ｈｃｖ) 전구약물 제형 |
| EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
| US7799790B2 (en) * | 2006-07-20 | 2010-09-21 | Helm Ag | Amorphous aripiprazole and process for the preparation thereof |
| EP1935405A1 (en) | 2006-12-22 | 2008-06-25 | LEK Pharmaceuticals D.D. | Orally disintegrating tablets |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| GB2447898B (en) | 2007-03-24 | 2011-08-17 | Reckitt Benckiser Healthcare | A tablet having improved stability with at least two actives |
| WO2010055019A1 (en) * | 2008-11-12 | 2010-05-20 | Akzo Nobel Coatings International B.V. | Polymer dispersions of narrow particle size distribution |
| DE102009015702A1 (de) | 2009-03-31 | 2010-10-07 | Ratiopharm Gmbh | Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung |
| GB201020895D0 (en) | 2010-12-09 | 2011-01-26 | Euro Celtique Sa | Dosage form |
-
2009
- 2009-06-05 GB GBGB0909680.1A patent/GB0909680D0/en not_active Ceased
-
2010
- 2010-06-07 KR KR1020127000058A patent/KR101816130B1/ko not_active Expired - Fee Related
- 2010-06-07 WO PCT/GB2010/050948 patent/WO2010140007A2/en not_active Ceased
- 2010-06-07 NZ NZ596879A patent/NZ596879A/xx not_active IP Right Cessation
- 2010-06-07 MX MX2011012929A patent/MX2011012929A/es active IP Right Grant
- 2010-06-07 CN CN2010800344131A patent/CN102481260A/zh active Pending
- 2010-06-07 CN CN201610970584.4A patent/CN106667919A/zh active Pending
- 2010-06-07 CA CA2764517A patent/CA2764517C/en not_active Expired - Fee Related
- 2010-06-07 BR BRPI1012004A patent/BRPI1012004A2/pt not_active Application Discontinuation
- 2010-06-07 EP EP10725263.7A patent/EP2437729B1/en active Active
- 2010-06-07 SG SG10201402810XA patent/SG10201402810XA/en unknown
- 2010-06-07 JP JP2012513685A patent/JP5635082B2/ja not_active Expired - Fee Related
- 2010-06-07 MY MYPI2011005869A patent/MY173629A/en unknown
- 2010-06-07 ES ES10725263T patent/ES2713957T3/es active Active
- 2010-06-07 AU AU2010255502A patent/AU2010255502B2/en not_active Ceased
- 2010-06-07 EA EA201171389A patent/EA022801B1/ru not_active IP Right Cessation
- 2010-06-07 US US13/376,113 patent/US9814679B2/en active Active
- 2010-06-07 SG SG2011089273A patent/SG176304A1/en unknown
-
2011
- 2011-12-04 IL IL216748A patent/IL216748A0/en unknown
- 2011-12-14 ZA ZA2011/09221A patent/ZA201109221B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2437729A2 (en) | 2012-04-11 |
| MX2011012929A (es) | 2012-04-20 |
| WO2010140007A3 (en) | 2011-11-17 |
| EP2437729B1 (en) | 2019-01-23 |
| CA2764517A1 (en) | 2010-12-09 |
| SG176304A1 (en) | 2012-01-30 |
| CN106667919A (zh) | 2017-05-17 |
| EA201171389A1 (ru) | 2012-05-30 |
| GB0909680D0 (en) | 2009-07-22 |
| KR101816130B1 (ko) | 2018-01-08 |
| AU2010255502B2 (en) | 2016-09-22 |
| NZ596879A (en) | 2013-06-28 |
| WO2010140007A2 (en) | 2010-12-09 |
| SG10201402810XA (en) | 2014-08-28 |
| CN102481260A (zh) | 2012-05-30 |
| ZA201109221B (en) | 2012-08-29 |
| JP5635082B2 (ja) | 2014-12-03 |
| IL216748A0 (en) | 2012-02-29 |
| KR20120026595A (ko) | 2012-03-19 |
| US20120135075A1 (en) | 2012-05-31 |
| WO2010140007A9 (en) | 2012-01-19 |
| ES2713957T3 (es) | 2019-05-24 |
| MY173629A (en) | 2020-02-12 |
| AU2010255502A1 (en) | 2012-01-12 |
| EA022801B1 (ru) | 2016-03-31 |
| CA2764517C (en) | 2017-07-04 |
| JP2012528845A (ja) | 2012-11-15 |
| US9814679B2 (en) | 2017-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1012004A2 (pt) | "forma farmacêutica" | |
| CY2018030I1 (el) | Φαρμακοτεχνικη μορφη 514 | |
| BR112012010595A2 (pt) | "dispensdor" | |
| BR112012012872A2 (pt) | "pirrolindinas de espiroindolinona" | |
| BRPI1011813A2 (pt) | "inalador" | |
| BRPI1008023A2 (pt) | forma de dosagem sólida | |
| DK3097925T3 (da) | Farmaceutisk sammensætning | |
| BRPI0920521A2 (pt) | combinação farmacêutica | |
| BRPI1010909A2 (pt) | "inseticida arilpirrolinas" | |
| BRPI1004940A2 (pt) | composição farmacêutica | |
| EP2471786A4 (en) | aminopyrazole derivative | |
| SMT201700095B (is) | Composizioni farmaceutiche per inalazione | |
| BR112012007164A2 (pt) | "veículo" | |
| BRPI1013030A2 (pt) | "aquecedores" | |
| BRPI1015939A2 (pt) | composição farmacêutica | |
| FR2944062B1 (fr) | Injecteur d'ergols | |
| BRPI0922653A2 (pt) | preparação farmacêutica | |
| BRPI0807882A2 (pt) | Forma de dosagem | |
| SMT201600041B (it) | Agenti terapeutici 713 | |
| BR112012003149A2 (pt) | composição farmacêutica | |
| EP2628733A4 (en) | ACYLBENZEN DERIVATIVE | |
| BRPI1009730A2 (pt) | "recipiente" | |
| EP2502909A4 (en) | aminopyridine derivative | |
| MA30860B1 (fr) | Myrtillier denomme "c97-390" | |
| BRPI1013017A2 (pt) | "17beta-alquil-17alfa-óxi-estratrienos" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: EURO-CELTIQUE S.A. (LU) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |